About The Experts

Scroll down to see all expert bios

Joy Aho

Dr. Joy Aho

Manager of Product Development for the Stem Cell and Cell Culture Department
R&D Systems

Dr. Aho received a Ph.D. in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota – Twin Cities and has over 10 years of experience developing media, reagents, and differentiation kits for stem cells.


Moderated Questions

Dr. Christian Weilke, Ph.D.,

Christian Weilke, Ph.D.,

International Product Manager
Roche Custom Biotech

Dr. Christian Weilke, Ph.D., International Product Manager at Roche Custom Biotech, will be answering your questions regarding the IgG assay and the Cedex Bio and Bio HT Analyzers. Christian holds a Ph.D. in chemistry and joined Roche in 1999. Since 2010, he has been working in Custom Biotech holding several different positions, and is currently responsible for the Pharma In-process Control portfolio.


Moderated Questions

Dr. Roger Noble, Ph.D., Lead Technical Support Consultant at Roche Custom Biotech

Dr. Roger Noble, Ph.D.

Lead Technical Support Consultant
Roche Custom Biotech

Dr. Noble has been with Custom Biotech for more than 15 years in various roles supporting customers’ applications for tissue dissociation, cell culture, immunological assays, clinical chemistry, molecular testing and bioprocess control. He holds a Master’s and Ph.D in Microbiology from Utah State University, and completed his Post-doc Research Fellowship at University of Michigan.


 

Moderated Questions

Dr. Juan Hou

Dr. Juan Hou

Senior Scientist, Epithelial Cell Biology
STEMCELL Technologies

Dr. Juan Hou is a Senior Scientist with the Epithelial Cell Biology team at STEMCELL Technologies, and oversees the PneumaCult™ line of products for airway epithelial cell research. Dr. Hou obtained her PhD in Developmental Biology from Osaka University, Japan. Before joining the Research and Development department at STEMCELL Technologies in 2012, she was a Research Associate investigating the signaling pathways regulating definitive endoderm formation and patterning at the Terry Fox Laboratory, BC Cancer Research Centre in Vancouver, Canada.


Moderated Questions

Dr. Adam Elhofy, Ph.D., CSO.

Dr. Adam Elhofy, Ph.D., CSO.


Essential Pharmaceuticals

Dr. Elhofy developed the core technology for the Ess line of products and aided in creating patents around novel uses of materials. Dr. Elhofy has over 14 years of scientific research experience in the areas of immunology, neuroscience, and oncology. He was funded by both the National Institutes of Health and the Multiple Sclerosis society as an investigator at Northwestern University Medical School. His doctoral research won him the award of the Top 5 trainee scientists by the American Association of Immunologists. Dr. Elhofy has 14 scientific publications in peer reviewed journals. He has played a variety of roles with start-up biotech companies ranging from Principal Investigator to Director of Corporate Development.


Moderated Questions

Katie Golson

Katie Golson

Biomedical Automation Application Engineer
Izumi International, Inc.

Katie Golson of Izumi International, Inc. Katie joined Izumi in 2014 as a Biomedical Automation Application Engineer where she helps develop customized laboratory automation and bioprinting solutions for companies and universities all over the world. She holds a Master’s in Bioengineering from University of California, San Diego and a Bachelor’s in Industrial Design from Georgia Institute of Technology. Her prior experience running automated liquid handling at Vertex Pharmaceutical.


Moderated Questions

Dr. Michael Riedel

Dr. Michael Riedel

Senior Scientist for Epithelial Cell Products in R&D
STEMCELL Technologies

Dr. Michael Riedel is a Senior Scientist and the team lead for epithelial cell products in R&D at STEMCELL Technologies. Dr. Riedel’s team develops cell culture media and reagents for the isolation, expansion and differentiation of both primary and pluripotent stem cell-derived epithelial cells from tissues including the pancreas, liver, lung and intestine. Dr. Riedel obtained his PhD from the University of Alberta and received postdoctoral training at the University of British Columbia where his work focused on the development of cell and gene therapies for diabetes.


Moderated Questions

Dr. Susan Burke

Dr. Susan Burke

Material Science Leader in BioProcess R&D
GE Healthcare

Susan Burke. Dr. Burke joined GE Healthcare in 2015 in the role of Material Science Leader in BioProcess R&D. She holds a Ph.D. in Materials Chemistry from McGill University and has expertise in polymer technologies for healthcare applications. Prior to joining GE Healthcare, she spent more than ten years in various R&D roles within the pharmaceutical and medical device industries overseeing product and process development initiatives.


Moderated Questions

Principal Scientist for Hematopoietic & Immunopoietic Products in R&D

Dr. Bert Wognum

Principal Scientist for Hematopoietic & Immunopoietic Products in R&D
STEMCELL Technologies

Dr. Bert Wognum is the Principal Scientist for Hematopoietic & Immunopoietic Products in R&D at STEMCELL Technologies, and currently leads the development of new media and supplements for the expansion, differentiation and detection of HSPCs in culture. Dr. Wognum obtained his PhD at the University of Amsterdam in the Netherlands and worked as a postdoctoral fellow at the Terry Fox Laboratory in Vancouver, Canada, and the Department of Hematology at Erasmus University in Rotterdam, the Netherlands. He studied the role of hematopoietic growth factors and their receptors in normal hematopoiesis and leukemia and contributed to preclinical studies aimed at improving hematopoietic recovery after cytoreductive therapy and transplantation.


Moderated Questions

Xin Yu Life ATE

Xin Yu

R&D scientist
Thermo Fisher Scientific, Inc

Xin Yu is an R&D scientist with more than 10 years of experience working on in vitro transfection . She was one of members who developed Lipofectamine® RNAiMax, LTX and 3000 reagents. She was the key person in conducting the App Note – LentiVirus Production by using Lipofectamine® 3000.


Moderated Questions

Virginia Spencer

Dr. Virginia Spencer

R&D scientist
ThermoFisher Scientific

Virginia Spencer is a R&D scientist with a PhD in biochemistry and epigenetics. She completed  a post-doc at Lawrence Berkeley National Lab  and has extensive experience in live cell fluorescence imaging. Virginia has been working as a R&D scientist for ThermoFisher Scientific since 2010 and is currently developing products for improving cell culture performance and the live cell imaging experience.


 

Moderated Questions

Jonathan Zmuda, Ph.D

Jonathan Zmuda, Ph.D.

Associate Director of Cell Biology in the Life Sciences Solutions Group
Thermo Fisher Scientific, Inc

Jonathan Zmuda, Ph.D. is the Associate Director of Cell Biology in the Life Sciences Solutions Group at Thermo Fisher Scientific, Inc. Prominent among his roles, Dr. Zmuda leads a team dedicated to discovering and developing new technologies and products useful for cell biology applications including protein expression, cell culture, rare cell analysis and instrumentation. Dr. Zmuda received his Ph.D. in Cell Biology from the University of Maryland, College Park and his undergraduate degree from Dickinson College in Carlisle, PA.


Moderated Questions

Ryan Conder, PhD

Ryan Conder, Ph.D

Senior Scientist, Epithelial Cell Biology
STEMCELL Technologies

Ryan is a Senior Scientist with the Epithelial Cell Biology team at STEMCELL Technologies. He is responsible for products relating to 3D intestinal organoid culture, including IntestiCult™ Organoid Growth Medium (Mouse). Prior to joining STEMCELL Technologies, Ryan investigated the mechanisms of asymmetric cell division in the adult intestine with Juergen Knoblich at the Institute for Molecular Biotechnology of the Austrian Academy of Sciences.


Moderated Questions

Dr. Rhonda Newman

Rhonda Newman, Ph.D.

Staff Scientist
Life Technologies

Dr. Newman joined Life Technologies in 2010 and is currently working on next generation stem cell culture and differentiation systems, enabling researchers to efficiently culture, expand, cryopreserve, and differentiate their stem cells to various cellular lineages. She received a Ph.D. at the University of Iowa from the lab of Dr. Madeline Shea, focusing on ligand induced allostery of calmodulin and its impact on regulation of the Ryanodine Receptor Type 1. Subsequently, she completed postdoctoral training in the lab of Dr. Ken Prehoda at the University of Oregon, studying the role of intramolecular interactions in regulating cell signaling cascades in the process of assymetric stem cell division.


Moderated Questions

Wing Chang, PhD

Wing Chang, PhD

Scientist
STEMCELL Technologies

Wing Chang, PhD, joined STEMCELL Technologies’ Research and Development Department in 2012 as a Scientist and is responsible for the development of products for reprogramming and the generation of induced pluripotent stem cells.  Prior to joining STEMCELL, Wing was a postdoctoral fellow at the Ottawa Hospital Research Institute and the University of Toronto.


Moderated Questions

Namritha Ravinder, Ph.D, Staff Scientist, Synthetic Biology Division, Life Technologies

Namritha Ravinder, Ph.D,

Staff Scientist, Synthetic Biology Division
Thermo Fisher Scientific

Namritha is the R&D lead for genome editing product development within the Synthetic Biology group at Thermo Fisher Scientific. Her team focuses on building tools and products for Genome and Cell Engineering applications. Prior to this role, she was part of the Synthetic Biology Custom services team and was involved in designing customized workflows that included a variety of Life Technologies platforms including cDNA library generation, Cloning, Next Generation Sequencing, RNAi and TaqMan qPCR. She has a Masters degree in Biochemistry from India and a Doctoral degree in Plant Molecular Biology and Biotechnology from University of Alabama. She did her Postdoctoral research at Children’s Hospital in Los Angeles where she was involved in studying the Mechanism of “Enhancement of virus release” by HIV accessory proteins Vpu and Env as well as identifying their respective host cellular restriction factors.


Moderated Questions

Ken Clapp

senior global product manager for single-use stirred-tank bioreactors and fermentors
GE Healthcare Life Sciences

Mr. Clapp is the senior global product manager for single-use stirred-tank bioreactors and fermentors. He holds a Bachelor’s degree in biology with a specialization in sub-cellular biology. He received a Masters degree in biological engineering, focused on biological control systems, mathematical modeling and instrumentation. Early in his career he worked as a media chemist, produced antigens and antibodies in large scale, and developed hollow-fiber based bioreactors. Over the past 25 plus years, Kenneth has worked in a variety of roles with bioprocess equipment manufacturers, including field service, sales & marketing, applied research & development, quality assurance, automation, manufacturing and operations management. He has been involved with and responsible for bioprocess equipment capital projects, spanning multi-vessel benchtop systems through large-scale, multiple train production facilities


 

Moderated Questions

Dr. Mohan C Vemuri

Dr. Mohan C Vemuri

Director of Research and Development for Cell Biology
Thermo Fisher Scientific.

Dr. Vemuri is the Director of Research and Development for Cell Biology at Thermo Fisher Scientific. In this capacity, Dr. Vemuri leads R&D activities in stem cell product development in the areas of human iPSC, adult stem cells, immune cells and cell lineage specific differentiation in GMP environment for research use and subsequently for use in cell therapy with regulatory compliance.

Prior to this role, Dr. Vemuri served on the faculty at Children’s Hospital of Philadelphia where his research efforts focused on developing improved methods for fetal transplantation of engineered hematopoietic stem cells for blood and bone marrow transplantation. Dr. Vemuri previously served on the faculty at Thomas Jefferson Medical School, where he developed cell screening assay systems for Parkinson’s disease drug discovery. Dr. Vemuri collaborates with researchers in academia and industry, striving towards the successful utilization of stem cells in regenerative cell therapies. He holds a Ph.D in Cell Biology from Sri Venkateswara University in India and performed his postdoctoral work at the National Institutes of Health.

Dr. Vemuri has authored over 50 publications and has edited or co-edited several stem cell focused books, including Stem Cell Assays, Regulatory Networks in Stem Cells, MSC assays and applications, MSCs and Cell Therapy, Neural Development and Stem Cells and most recently, Pluripotent Stem Cell Assays by Springer Press.


Moderated Questions

Jose-Castillo

Jose Castillo

Director of Cell Culture Technologies
Pall Life Sciences

Jose Castillo transitioned into his role as Director of Cell Culture Technologies for Pall Life Sciences during the December 2013 acquisition of ATMI LifeSciences. Before this time, Jose was one of the original founders and acting CTO at Artelis, which ATMI LifeSciences acquired in November 2010.

Throughout his career, Jose has been heavily entrenched in development aspects for “process intensification” in disposable bioreactors and related processes for vaccine and antibody applications, as well as for the expansion of stem cells.

Prior to founding Artelis, Jose worked as the Manager of Viral Vaccine Industrialization for GSK Biologicals. He has a general background in Chemical Engineering, including a PhD in Applied Sciences from the Université libre de Bruxelles, and an entrepreneurship degree from the Solvay Business School.


Moderated Questions

Dr. Vivian Lee

Senior Scientist
STEMCELL Technologies

Vivian Lee, PhD, is a Senior Scientist in STEMCELL Technologies’ Research and Development department, responsible for the development of products for neural tissues and pluripotent stem cells. Before joining STEMCELL, Vivian was a Principal Investigator at the Medical College of Wisconsin, studying the genetic regulation of neural stem cell development.


Moderated Questions

Uma Lakshmipathy

Dr Uma Lakshmipathy

Principal Scientist
Thermo Fisher Scientific

Dr. Uma Lakshmipathy has been involved in the field of stem cells for nearly a decade. Her doctoral degree in Molecular Biophysics and subsequent postdoctoral experience in DNA repair brought new perspective and led her to the area of stem cell research with focus on developing ex vivo gene repair systems. As a junior faculty at the Stem Cell Institute, University of Minnesota, she identified efficient gene delivery methods into stem cells to enable repair of adult stem cells from monogene disorders. She moved to Invitrogen, Life Technologies, in 2005 and was involved in the development of novel technology platforms for creating labeled stem cells. Her current research interests at Life Technologies, now a part of Thermo Fisher Scientific, are regulation of stem cell maintenance, development of technologies for generation, identification, characterization of pluripotent stem cells, and modification their derivatives.


Moderated Questions

Dr. Rupa Shevde

Dr. Nirupama Shevde

Customer Training Manager
Life Technologies

Dr. Nirupama (Rupa) Shevde is the Customer Training Manager in the Primary and Stem Cell Systems group at Life Technologies. She obtained her doctorate at Harvard University and her postdoctoral training at USCD and Ligand Pharmaceuticals in San Diego, CA. She has extensive experience in both mouse and human pluripotent stem cell research and served as a Senior Scientist and Director of Education at WiCell Research Institute and Morgridge Institute for Research since 2005 until July 2012. Under the scientific leadership of Dr. James Thomson, Rupa developed the Stem Cell Training Course which has served over 800 scientists from 32 US states and 20 countries. Most recently, Rupa was able to work in Dr. Thomson’s laboratory and gain expertise in the novel Essential 8™ Medium, Vitronectin (VTN-N) substrate and non-integrating episomal reprogramming technology developed by Dr. James Thomson and marketed by Life Technologies.


Moderated Questions

David Judd

product manager of global research sera products
ThermoFisher Scientific

David Judd is the product manager of global research sera products for the Biosciences Division of ThermoFisher Scientific. David has worked for ThermoFisher for 24 years in cell culture products and applications. David has a broad array of experience in  development of media for primary cells and cell lines. He has developed manufacturing processes, cell assays, biochemical analysis, cell culture processes and downstream recovery strategies. He has stepped out of the lab in order to find new ways to provide new workflow solutions for serum products for cell culture applications.


Moderated Questions

Nektaria Andronikou


Life Technologies

Nektaria Andronikou joined Life Technologies in 2010 and is currently working with the transfection team on the development of new delivery methods targeting relevant cellular models that will enable the use of exciting new technologies.  She received a Bachelor of Science in Biochemistry with a minor in Cellular and Molecular Biology from UCSD.  She began her professional career at ISIS Pharmaceuticals, as a research associate for the Cardiovascular Drug Discovery program, screening numerous pre-clinical targets that led to the discovery of the now FDA approved antisense drug, Kynamro.


Moderated Questions

Jolene Bradford

R&D Associate Director
Thermo Fisher Scientific

Jolene Bradford, R&D Associate Director in Eugene, Oregon, USA working in the Biosciences Division of Thermo Fisher Scientific (formerly Life Technologies).  Jolene joined Molecular Probes® Labeling and Detection Technologies in 2001, where she has developed new reagents and assays for the flow cytometry platform.  Well versed in fluorescent assays to evaluate proliferation and cellular health, Jolene has provided numerous webinars and seminars on the topics. She has been an invited instructor at many flow cytometry training courses and workshops, both in the US and abroad.   More recently she has been involved in developing acoustic cytometry. Prior to joining Molecular Probes, Jolene spent over 20 years in healthcare performing clinical laboratory testing as a specialist in hematology and flow cytometry.


Moderated Questions

jolene-bradford

Jolene Bradford

R&D Associate Director
Thermo Fisher Scientific

Jolene Bradford, R&D Associate Director in Eugene, Oregon, USA working in the Biosciences Division of Thermo Fisher Scientific (formerly Life Technologies).  Jolene joined Molecular Probes® Labeling and Detection Technologies in 2001, where she has developed new reagents and assays for the flow cytometry platform.  Well versed in fluorescent assays to evaluate proliferation and cellular health, Jolene has provided numerous webinars and seminars on the topics. She has been an invited instructor at many flow cytometry training courses and workshops, both in the US and abroad.   More recently she has been involved in developing acoustic cytometry. Prior to joining Molecular Probes, Jolene spent over 20 years in healthcare performing clinical laboratory testing as a specialist in hematology and flow cytometry.


Moderated Questions

Peggy Lio Director of Process Science at GE Healthcare

Peggy Lio

Director of Process Science
GE Healthcare

Peggy is currently Director of Process Science at GE Healthcare where she is responsible for leading the technical applications strategy for the US cell culture business. She joined GE from Life Technologies where she was responsible for the development of PD-Direct Bioprocess custom cell line and cell culture media optimization service programs globally. She also led an applications team charged with scientific support of new cell line and media products as well as process development. Prior to Life Technologies, Peggy held roles of increasing responsibility with Schering-Plough Corp., where she ultimately became Section Leader with responsibility for mammalian and microbial fermentation process development for a variety of biotechnology based therapeutics. Peggy has over 30 years of extensive technical and commercial experience in bioprocessing along with multiple honors and awards from Schering and Life Technologies.


Moderated Questions

Randall Alfano

Randall Alfano

Cell Culture Scientist
Invitria

Randall Alfano, Cell Culture Scientist, joined InVitria in 2012. He currently develops animal free proteins and supplements for various cell systems including stem cells. He  has over  6 years’ experience in recombinant protein expression and purification as well as medium development for CHO-based biomanufacturing and stem cells. Randall was awarded his Ph.D. in 2009 from the Texas A&M College of Medicine Health Science Center in Cell Biology.


Moderated Questions

Paul J. Price, Ph.D

Media Design Consultant

Dr. Price has been a research scientist for over 50 years. Positions he has held include Branch Chief in the Center for Infectious Diseases at the CDC, and founder and Executive Vice-President of Hycor Biomedical. As a Research Fellow at Life Technologies, he helped design much of the specialized media used around the world for the culture (growth) of neurons, stem cells and other mammalian cells, including those used in Bio-Production. He is currently a consultant to several human health companies wanting to develop products in both the areas of Regenerative Medicine and Bio-Production. In June of this year he was awarded a Distinguished Lifetime Achievement Award by the Society for In Vitro Biology for his role in moving research forward in the production of products from cells (Biotechnology) and the use of cells as products (Regenerative Medicine).


Moderated Questions

Patrick Guertin

Patrick Guertin

Patrick Guertin
Xcellerex - GE Healthcare Life Sciences

Patrick Guertin, Senior Manager, Upstream Process Development and Pilot Plant, Xcellerex, now part of GE Healthcare Life Sciences.  Mr. Guertin has 25 years of experience and significant expertise in upstream process development, pilot plant operations and cGMP manufacturing for recombinant therapeutics, monoclonal antibodies and vaccines. His skill set also includes process optimization and scale-up and down procedures in microcarrier, fed-batch and perfusion modes.

Curriculum Vitae and Qualifications

M.S. Biochemistry – Northeastern University
B.S. Biology – Boston College

  • 2006 to present: Sr. Manager USPD & Pilot Plant, Xcellerex/GE Healthcare
  • 2001-2006: Staff Scientist – Manager Cell Culture Development, Genzyme
  • 1998-2001 Manager cGMP Manufacturing, UNISYN Technologies
  • 1991-1998: Supervisor-Assoc.  Scientist Process Development, Creative  BioMolecules
  • 1988-1991: Associate Scientist, Damon Biotech

Expertise and Relevant Experience

  • Upstream process development, pilot plant operations and cGMP manufacturing for recombinant therapeutics, monoclonal antibodies and vaccines.
  • Scale-up, scale-down, suspension, microcarrier, fed-batch, perfusion modes.
  • Process optimization traditional and single-use mammalian and microbial bioreactors
  • ADC-free media and feed development
  • Technology transfer, process design  and data analysis

Moderated Questions

Paul A. Offit, MD

Dr. Paul A. Offit

Author, Chief of the Division of Infectious, and Director of the Vaccine Education Center at the Children’s Hospital of Philadelphia

Paul A. Offit, MD is the Chief of the Division of Infectious Diseases and the Director of the Vaccine Education Center at the Children’s Hospital of Philadelphia. In addition, Dr. Offit is the Maurice R. Hilleman Professor of Vaccinology and a Professor of Pediatrics at the University of Pennsylvania School of Medicine. He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, and a Research Career Development Award from the National Institutes of Health. Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC; for this achievement Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases; and was honored by Bill and Melinda Gates during the launch of their Foundation’s Living Proof Project for global health.

He is also the author of five medical narratives: The Cutter Incident: How America’s First Polio Vaccine Led to Today’s Growing Vaccine Crisis (Yale University Press, 2005), Vaccinated: One Man’s Quest to Defeat the World’s Deadliest Diseases (HarperCollins, 2007), for which he won an award from the American Medical Writers Association, Autism’s False Prophets: Bad Science, Risky Medicine, and the Search for a Cure (Columbia University Press, 2008), Deadly Choices: How the Anti-Vaccine Movement Threatens Us All (Basic Books, 2011), and Do You Believe in Magic?: The Sense and Nonsense of Alternative Medicine (HarperCollins, 2013).


Moderated Questions

Neil Littman, the Business Development Officer at the California Institute for Regenerative Medicine (CIRM)

Neil Littman

Business Development Officer
California Institute for Regenerative Medicine (CIRM)

Mr. Littman is responsible for facilitating opportunities for outside investment in stem cell research in California for both CIRM-funded and non CIRM-funded programs by biopharmaceutical strategic partners, equity investors, and disease foundations.

Prior to joining CIRM in 2012, Mr. Littman was a Senior Associate in the Merchant Banking Group at Burrill & Company, a diversified global financial services firm focused on the life sciences industry based in San Francisco.  While at Burrill & Company, Mr. Littman’s responsibilities included both strategic advisory and capital raising assignments for biopharmaceutical companies throughout the U.S. and internationally.

Mr. Littman’s strategic advisory experience includes buy-side and sell-side M&A, as well as in-licensing and out-licensing of both development stage and commercial products.  Prior to joining Burrill & Company in 2009, Mr. Littman worked in the Healthcare Investment Banking group at Thomas Weisel Partners where he focused on strategic advisory assignments and public and private financings. Prior to Thomas Weisel Partners, Mr. Littman worked in the Healthcare Investment Banking group at Deutsche Bank Securities.

Mr. Littman received a Master of Science in Biotechnology with a concentration in Biotechnology Enterprise from The Johns Hopkins University, and a Bachelor of Arts in Molecular, Cellular and Development Biology from the University of Colorado Boulder in 2002.


Moderated Questions

Dr. Graziella Mendonsa

Dr. Graziella Mendonsa

Product Manager
MIDSCI since

Dr. Graziella Mendonsa obtained her Ph.D. and T32 NIH Post-doctoral fellowship from Washington University School of Medicine in St. Louis, in addition to a BA degree in Biochemistry and Biology with an Honors in Biochemistry from Knox College. Her experience as a scientist and an end-user of MIDSCI’s extensive product portfolio during her educational training, prepared her for her current roles of product launch, evaluation and marketing at MIDSCI. With her extensive background in tissue culture, she is excited to be immersed in technological advancements provided by MIDSCI’s premium cell cultureware line TPP and the latest breakthroughs in the N3D Bioscience product line distributed nationally by MIDSCI.


Moderated Questions

Carla Conant, Global Product Manager, ATMI LifeSciences

Carla Conant

Global Product Manager
ATMI LifeSciences

Carla Conant joined ATMI LifeSciences in May of 2013 as a Global Product Manager focused on the Integrity® suite of products and technologies. She brings over a decade of experience in the biopharmaceutical industry and single-use plastics to this role, complemented by a rich background of brand management, promotion and product development. Carla holds an MBA in Finance and a double Bachelor in International Business & Economics and Spanish.


Moderated Questions

Christian Kaisermayer

Christian Kaisermayer

Senior Scientist
GE Healthcare

Christian Kaisermayer, currently holds the position of senior scientist at GE Healthcare. He is project manager for the development of cell culture media for vaccine applications and is based in Uppsala, Sweden. Christian also provides customer support and is involved in the scale up of virus propagation processes. He joined GE in 2007 and as a specialist for microcarrier applications supported several design-in projects and marketing activities. Christian then moved to a position in Fast Trak, a GE organization providing customer training and process development. In this function he developed several cell culture and bioreactor courses and trained customers in Europe, the US and Asia. Christian ran numerous application and process development projects related to single use bioreactors and microcarriers. Much of this work has been done in a research cooperation with a Vienna university institute that he is managing.

Christian has several years of experience in the development of fedbatch and perfusion processes for recombinant protein production and in the cultivation of adherent cells at laboratory and pilot scale. He received his PhD in Biotechnology from the University of Natural Resources and Applied Life Sciences in Vienna and also holds an engineering degree in Food Science and Biotechnology.


Moderated Questions

Erin Hall

Erin Hall, M.S.

Director of Cell Line Authentication Services
Gentica DNA Laboratories, LabCorp Specialty Testing Group

Erin M. Hall, M.S., is Director of Cell Line Authentication Services, Genetica DNA Laboratories, LabCorp Specialty Testing Group. Erin received a master’s degree in Forensic Science from Pace University in New York City and a bachelor’s degree in Molecular Biology from the College of Mount Saint Joseph in Cincinnati, Ohio. Prior to joining Genetica, Erin worked as a laboratory manager and researcher in the Pharmacology department at Cornell University’s Weill Cornell Medical College. She designed and executed complex experiments that examined the effects of environmental toxins on liver enzyme production utilizing HPLC, UV/vis spectroscopy, Western blot, and PCR analysis. Her work contributed to several published journal papers (under Erin Labitzke), most recently including being cited as first author on a paper related to enzymes present in mitochondria.


Moderated Questions

Jonathan Gross Labguru picture

Jonathan Gross

Founder and CTO
BioData

Jonathan founded BioData out of his passion to integrate technology and science. In addition to founding the company, Jonathan is also the Chief Technologist of the company. Jonathan holds a B.A. in Computer Science from the Interdisciplinary Center (IDC) Herzliya and a Masters degree in Biotechnology from the Hebrew University of Jerusalem. As a scientific researcher Jonathan worked on enhancing the nutritional value of plants through molecular engineering and plastid transformation. Jonathan is also one of the founders of The BioExecutive Forum, a non-profit organization founded by and for executives from the Israeli Biomed industry.


Moderated Questions

Ronnda Bartel

Ronnda Bartel, Ph.D.

Chief Scientific Officer
Aastrom Biosciences

Ronnda joined Aastrom Biosciences in 2006 and is responsible for the scientific direction of the company, including research, development and technical operations.  She has more than 20 years of research and product development experience and most recently was executive director, biological research at MicroIslet and vice president, scientific development at StemCells Inc.

Earlier in her career, she was senior principal scientist and director of research at Advanced Tissue Sciences and was involved in the development and approval of some of the first cell-based products approved by the FDA. She has also worked as senior director, science and technology at SRS Capital, LLC evaluating life science investments and has held positions in clinical development, drug delivery, business development and manufacturing. Ronnda holds a PhD in biochemistry from the University of Kansas, has completed postdoctoral work at the University of Michigan and received a BA in chemistry and biology from Tabor College.

For more information, please see Ronnda’s previous guest blog “From Product Candidate to Product – The Road to Commercialization in Regenerative Medicine.


Moderated Questions

Caroline Hornby

Caroline Hornby

Marketing Director
Terrapinn Inc, USA

Caroline Hornby has been in the conferencing industry since 2006, and has worked in both Europe and the US, and across a variety of regions and industries, from life sciences to transport to finance and trading.

Now based in New York, Caroline oversees the marketing department for Terrapinn’s Americas business, and is currently working on the marketing campaign for Cell Culture World Congress USA, which is taking place alongside Stem Cells & Regenerative Medicine Congress and World Cord Blood Congress in Cambridge, MA this September.

A firm believer in networking – both online and in person – Caroline has experience in all things conference-related, from choosing the right event for your business needs, to preparing for the event prior to arrival, to making the most out of the on-site experience. This makes her the right person to help you get the most value out of attending a conference.


Moderated Questions

Dr. Fawcett - Director of the BioTechnical Institute of Maryland (BTI)

Timothy Fawcett, Ph.D.

Director
BioTechnical Institute of Maryland

Timothy Fawcett, Ph.D. has been in the biotechnology business for over 30 years. Trained as a biochemist he has held senior positions in both academics and industry and has been a mentor to many young scientists throughout his career.

For the last 12 years Dr. Fawcett has been the Director of the BioTechnical Institute of Maryland (BTI) a non-profit institute located in Baltimore, Maryland. He is also the Founder and Director of BioSciConcepts, a social venture of BTI that provides hands-on training for professional scientists in cell culture, baculovirus based expression, as well as topics such as molecular biology, PCR and real-time PCR. BioSciConcepts is an internationally recognized provider of expertise in the biological sciences and has provided consultation services to several small and large biotechnology companies.

Dr. Fawcett has a deep knowledge of biotechnology and has experience in most of the technical aspects of the workflow. This makes him the person to help you perform your job better

Moderated Questions